Main Article Content


In this study we assessed the cost-of-illness which involves measuring the direct and indirect costs incurred by Type 2 Diabetes Mellitus [T2DM] patient. The quality of life [QOL] of patients was measured using Quality of Life Instrument for Indian Diabetes Patients which is a questionnaire to assess the Indian diabetic patients. Adherence with medication usage is the measurement of prescribed doses of medication actually taken by a patient over a certain period of time. Patient’s demographic details, medication, medical history duration, hospital stay as well as treatment and clinical profile of the patients were assessed. The direct medical and direct nonmedical cost will be documented. A validated questionnaire will be given to the patient at baseline to assess their medication adherence and quality of life. Statistical analysis was performed using Graphpad InStat 3 software. ‘p value’ less than 0.05 was considered to be statistically significant. We observed that out of 130 patients, the total cost of illness is estimated as Rs.1,38,348 out of which 97.14% was direct medical cost and 2.85% were direct nonmedical cost. The patients with low adherence were the patient who had a higher cost of illness due to the worsening of the disease. Patient with high QOL were observed in <10year. Diabetes is one of the major lifestyle diseases that can be a risk factor for several complications. Physicians and Pharmacists should also adopt interventions that should be executed to help patients remind to keep their clinic appointments and to take their anti-diabetic medications as prescribed in order to lower the complications of diabetic mellitus and to raise the quality of life of the patients.


Diabetes mellitus quality of Life medication adherence cost of illness modified morisky medication adherence scale pharmaeconomics

Article Details

How to Cite
Sharlet Ann Johny, Anupriya A.P, Oleena John, Surekha G, & Padmaa M Paarakh. (2017). Evaluation of pharmacoeconomics, medication adherence and quality of life in type 2 diabetes mellitus patients. International Journal of Research in Pharmaceutical Sciences, 8(3), 315-320. Retrieved from